With regard to the therapy decision, one has to bear in mind that this is not exclusively achieved by molecular-based analysis as for EGFR mutations (Rosell et al, 2009), but also deeply depends upon the previous diagnosis of NSCLC and subdifferentiation into adenocarcinomas. The gene discussed is EGFR; the disease is adenocarcinoma.